摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-bromo-1-[4-bromo-3-[(methylsulfonyl)amino]phenyl]ethanone | 193762-58-2

中文名称
——
中文别名
——
英文名称
2-bromo-1-[4-bromo-3-[(methylsulfonyl)amino]phenyl]ethanone
英文别名
N-[2-bromo-5-(2-bromoacetyl)phenyl]methanesulfonamide
2-bromo-1-[4-bromo-3-[(methylsulfonyl)amino]phenyl]ethanone化学式
CAS
193762-58-2
化学式
C9H9Br2NO3S
mdl
——
分子量
371.049
InChiKey
QUUFXMAJFPGXAT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    71.6
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    METHOD FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES THROUGH AZIDES
    摘要:
    本发明涉及一种用于治疗和预防糖尿病、肥胖、高脂血症等疾病的三环氨基醇衍生物的制备方法,该化合物由以下式子表示(1): 其中R1代表较低的烷基或苄基;*1代表一个不对称碳原子;R2代表氢原子、卤素原子或羟基;A代表以下其中一种基团: 其中X代表NH、O或S;R5代表氢原子、羟基、氨基或乙酰氨基;*2代表一个不对称碳原子,当R5不是氢原子时。本发明的方法通过叠氮衍生物进行,是方便、实用、成本低廉的制备方法,包括少量步骤且具有良好的工业工作效率。
    公开号:
    EP1174426A1
  • 作为产物:
    描述:
    1-[4-bromo-3-[(methylsulfonyl)amino]phenyl]ethanone 在 作用下, 以 1,4-二氧六环正己烷乙酸乙酯 为溶剂, 生成 2-bromo-1-[4-bromo-3-[(methylsulfonyl)amino]phenyl]ethanone
    参考文献:
    名称:
    US6037362
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • Novel tricyclic compounds and drug compositions containing same
    申请人:ASAHI KASEI KOGYO KABUSHIKI KAISHA
    公开号:US20030139475A1
    公开(公告)日:2003-07-24
    Compounds having a &bgr;-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc., represented by a general formula (I) and salts thereof, and a process for producing these, and their intermediates, wherein R represents hydrogen or methyl; R 1 represents hydrogen, halogen, hydroxy, benzyloxy, amino, or hydroxymethyl; R 2 represents hydrogen, hydroxymethyl, NHR 3 , SO 2 NR 4 R 4′ , or nitro; R 6 represents hydrogen or lower alkyl; and X represents nitrogen, R 9 represents hydrogen, one of R 7 and R 8 represent hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy.
    具有&bgr;-3肾上腺素受体激动剂的化合物,可用于治疗和预防糖尿病、肥胖症、高脂血症等疾病,其通式表示为(I),并且包括其盐,以及制备这些化合物和其中间体的方法。其中,R代表氢或甲基;R1代表氢、卤素、羟基、苄氧基、氨基或羟甲基;R2代表氢、羟甲基、NHR3、SO2NR4R4′或硝基;R6代表氢或低碳基;X代表氮;R9代表氢;R7和R8中的一个代表氢,而另一个代表氢、氨基、乙酰氨基或羟基。
  • NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME
    申请人:Asahi Kasei Kogyo Kabushiki Kaisha
    公开号:EP0882707A1
    公开(公告)日:1998-12-09
    Compounds represented by general formula (I) or salts thereof, a process for producing the same, and intermediates therefor, wherein R represents hydrogen or methyl; R1 represents hydrogen, hologeno, hydroxy, benzyloxy, amino, or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4, or nitro; R6 represents hydrogen or lower alkyl; and X represents nitrogen, oxygen, sulfur, or methylene, provided that when X represents nitrogen, oxygen, or sulfur, then R9 represents hydrogen, one of R7 an R8 represents hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy, and when X represents methylene, then R7 and R8 each represents hydrogen and R9 represents hydrogen, amino, etc. They have a β-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc.
    通式(I)所代表的化合物或其盐类,以及生产该化合物或其盐类的工艺和中间体,其中R代表氢或甲基;R1代表氢、囟素、羟基、苄氧基、氨基或羟甲基;R2代表氢、羟甲基、NHR3、SO2NR4R4或硝基;R6代表氢或低级烷基;X代表氮、氧、硫或亚甲基,但当X代表氮、氧或硫时,R9代表氢,R7和R8中的一个代表氢,另一个代表氢、氨基、乙酰氨基或羟基;当X代表亚甲基时,R7和R8各自代表氢,R9代表氢、氨基等。它们具有β-3肾上腺素受体激动剂的作用,可作为治疗和预防糖尿病、肥胖症、高脂血症等的药物。
  • NOVEL TRICYCLIC COMPOUNDS HAVING SATURATED RINGS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
    申请人:Asahi Kasei Kogyo Kabushiki Kaisha
    公开号:EP0997458A1
    公开(公告)日:2000-05-03
    Compounds represented by general formula (I) or their salts, having β3 -adrenoceptor agonism and being efficacious when employed in drugs for treating and preventing diabetes, obesity, hyperlipemia, etc. wherein R represents hydrogen or methyl; R1 represents hydrogen, halogeno, hydroxy, benzyloxy, amino or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4', or nitro (wherein R3 represents hydrogen, methyl, SO2R5, formyl or CONHR6'; R5 represents lower alkyl, benzyl or NR4R4'; R4 and R4' may be the same or different and each represents hydrogen, lower alkyl or benzyl; and R6' represents hydrogen or lower alkyl); R6 represents hydrogen or lower alkyl; n is 1 or 2; X represents secondary nitrogen, oxygen or sulfur; and when n is 1, then one of R7 and R8 represents hydrogen while another represents hydrogen, amino, acetylamino or hydroxy, or when n is 2, then R8 represents hydrogen while R7 represents hydrogen, amino, acetylamino or hydroxy.
    通式(I)所代表的化合物或其盐类,具有 β3-肾上腺素受体激动作用,在用于治疗和预防糖尿病、肥胖症、高血脂症等药物时具有疗效。其中 R 代表氢或甲基;R1 代表氢、卤素、羟基、苄氧基、氨基或羟甲基;R2 代表氢、羟甲基、NHR3、SO2NR4R4'或硝基(其中 R3 代表氢、甲基、SO2R5、甲酰基或 CONHR6';R5 代表低级烷基、苄基或 NR4R4';R4 和 R4'可以相同或不同,各自代表氢、低级烷基或苄基;和 R6' 代表氢或低级烷基);R6 代表氢或低级烷基;n 为 1 或 2;X 代表仲氮、氧或硫;当 n 为 1 时,则 R7 和 R8 中的一个代表氢,而另一个代表氢、氨基、乙酰氨基或羟基,或当 n 为 2 时,则 R8 代表氢,而 R7 代表氢、氨基、乙酰氨基或羟基。
  • METHOD FOR IMPROVING THE SOLUBILITY OF TRICYCLIC AMINO ALCOHOL DERIVATIVES
    申请人:Asahi Kasei Kabushiki Kaisha
    公开号:EP1219604A1
    公开(公告)日:2002-07-03
    Compounds useful for treating and preventing diabetes, obesity, hyperlipidemia and so on are provided in the form of oral preparations exhibiting good absorbability in the digestive tract. A method for improving the solubility of tricyclic amino alcohol derivatives of the general formula (1) or salts thereof: wherein R1 represents a lower alkyl group or a benzyl group; * represents an asymmetric carbon atom; R2 represents a hydrogen atom, a halogen atom or a hydroxyl group; and A represents one of the following groups: wherein X represents NH, O or S, characterized by using these derivatives or salts in an amorphous state.
    可用于治疗和预防糖尿病、肥胖症、高脂血症等的化合物以口服制剂的形式提供,在消化道中具有良好的吸收性。一种改善通式(1)的三环氨基醇衍生物或其盐的溶解性的方法: 其中 R1 代表低级烷基或苄基; * 代表不对称碳原子; R2 代表氢原子、卤素原子或羟基;以及 A 代表下列基团之一 其中 X 代表 NH、O 或 S,其特征是以无定形状态使用这些衍生物或盐。
  • US6037362A
    申请人:——
    公开号:US6037362A
    公开(公告)日:2000-03-14
查看更多